BP Aqua Clen 80 is an aqueous injectable clenbuterol preparation marketed in South African research-chemical channels at a nominal 80 µg/mL, intended for in vitro beta-2 adrenergic agonist work where solvent load matters. The aqueous format sidesteps the DMSO (dimethyl sulfoxide) ceiling that constrains oral or powder-reconstituted dosing: 2023–2024 methods papers flag cytotoxicity and transcriptomic drift at ≥0.5% DMSO in HEK293, HepG2 and primary lines, whereas water-based stocks let researchers stay below the 0.1% solvent threshold while still hitting the 1 nM–1 µM working range typical of 2024–2025 β2 assays in 3T3-L1 adipocytes and airway smooth-muscle cultures.
Key Takeaways
- BP Aqua Clen 80 is a pre-dissolved aqueous injectable clenbuterol solution (80 µg/mL) for in vitro research, eliminating solvent artefacts that confound cell-culture assays.
- The aqueous format allows researchers to work at 1 nM–1 µM concentrations without exceeding the 0.1% DMSO cytotoxicity threshold documented in HEK293, HepG2 and primary cell lines.
- Clenbuterol is a selective β2-adrenergic agonist used across adipocyte lipolysis, airway smooth-muscle relaxation, skeletal-muscle signalling and metabolic-rate assays.
- In South Africa, clenbuterol is Schedule 4 under SAHPRA jurisdiction; institutional ethics approval and controlled-substance handling protocols are mandatory before use.
- Storage at 2–8 °C with light protection is required; no reconstitution step is needed because the product ships pre-dissolved.
What Is BP Aqua Clen 80?
BP Aqua Clen 80 is an aqueous injectable research solution containing 80 µg of clenbuterol hydrochloride (CAS 21898-19-1) per millilitre, manufactured by Body Pharm for laboratory use only. It is not a registered medicine and is not intended for human or veterinary consumption.
In preclinical research, BP Aqua Clen 80 is used as a reference beta-2 adrenergic agonist for in vitro assays, cAMP (cyclic adenosine monophosphate) signalling in HEK293-β2 cells, lipolysis profiling in 3T3-L1 adipocytes, and bronchodilator benchmarking in airway smooth-muscle cultures, typically across a 1 nM–1 µM working range. JCSG.org is one of the local distribution channels through which BP-line research compounds reach SA laboratories.
The water-based carrier distinguishes it from powder-reconstituted or oral formats such as the BP Clenbuterol 40 oral tablet format, removing the DMSO load that complicates solvent-sensitive assays. For broader context on formats and assay fit, see the clenbuterol research overview.
Quick product facts
- Active: clenbuterol hydrochloride, CAS 21898-19-1
- Concentration: 80 µg/mL (nominal, label claim)
- Carrier: aqueous (water-based)
- Manufacturer: Body Pharm (BP)
- Distribution in SA: JCSG.org and aligned research-chemical channels
- Use class: in vitro research reference compound; not for human use
Product Specifications at a Glance
The table below consolidates the technical attributes researchers typically check before allocating BP Aqua Clen 80 to an assay protocol. Store at 2–8 °C with protection from light to limit photodegradation across the working life of a vial.
| Attribute | Specification |
|---|---|
| Compound | Clenbuterol hydrochloride |
| CAS number | 21898-19-1 |
| Format | Aqueous injectable solution |
| Concentration | 80 µg/mL (label claim) |
| Purity claim | ≥98% HPLC (High-Performance Liquid Chromatography) (reseller-stated, lot-specific certificate of analysis on request) |
| Storage | 2–8 °C, protect from light |
| Classification | In vitro research reference compound; not for human or veterinary use |
| Manufacturer | Body Pharm (BP) |
For format benchmarking against a solid oral comparator, the BP Clenbuterol 40 oral tablet format sits within the same clenbuterol research overview category and supports parallel oral-versus-aqueous design comparisons.
Clenbuterol's Beta-2 Adrenergic Mechanism
Clenbuterol is a selective β2-adrenergic receptor (ADRB2) agonist that activates Gs-coupled adenylyl cyclase, elevates intracellular cAMP, and drives protein kinase A (PKA) phosphorylation of downstream effectors. In overexpressing HEK293-β2 systems, functional EC50 (half-maximal effective concentration) values sit in the low-nanomolar range (approximately 1–10 nM), with full Emax (maximum effect) typically reached by 100 nM. That receptor selectivity, combined with potent cAMP coupling, is why clenbuterol is routinely used as a positive-control ligand when profiling novel β2 agonists, often alongside salbutamol as a comparative reference.
Three downstream effects dominate the 2024–2025 literature:
Adipocyte lipolysis. PKA phosphorylates hormone-sensitive lipase (HSL) and perilipin, driving glycerol release. López-García et al. (2024) used clenbuterol as a β2 positive control to validate HSL phosphorylation and glycerol output in primary mouse adipocytes. Zhang et al. (2024) benchmarked 10–100 nM clenbuterol against biased agonists in differentiated 3T3-L1 cells.
Bronchial smooth-muscle relaxation. cAMP-driven PKA reduces myosin light-chain kinase activity, producing bronchodilation in airway smooth muscle. Singh et al. (2025) applied clenbuterol across 1 nM–1 µM in human airway smooth-muscle cultures and precision-cut lung slices as a comparator bronchodilator.
Anabolic skeletal-muscle signalling. β2-cAMP-PKA crosstalk with the mTOR (mechanistic target of rapamycin) / p70S6K pathway associates with skeletal muscle hypertrophy responses in preclinical muscle models, supporting clenbuterol's use as a reference anabolic β2 ligand.
Calorimetric tissue work. Brown adipose and soleus preparations apply 0.1–10 µM exposures to measure oxygen consumption shifts under sustained β2 activation.
Clenbuterol is a long-acting reference ligand because its elimination half-life is approximately 25–39 hours in humans and 10–35 hours across rats, dogs and horses. In buffered in vitro media, the compound remains chemically stable across standard 24–48 h assay windows, so apparent loss is dominated by uptake, binding and medium exchange rather than degradation.
Why Aqueous Injectable Format for In Vitro Research?
Aqueous injectable clenbuterol removes the tablet-dissolution and solvent-cytotoxicity variables that confound dose-response work in cell culture. Because BP Aqua Clen 80 is pre-dissolved at a stated 80 µg/mL in aqueous carrier, researchers can add it volumetrically to culture wells at known molar concentrations without an intermediate DMSO or ethanol step. That is the practical advantage over oral tablet formats. Researchers concerned about solvent artefacts in receptor-activation assays will find the pre-dissolved format eliminates this source of variability entirely.
Eliminating excipient and solvent confounders
Oral tablets must be crushed and dissolved in DMSO or ethanol before in vitro use. This introduces two artefact sources: residual excipients (binders, disintegrants, lactose) that can interfere with receptor-binding readouts, and organic-solvent cytotoxicity. Kim et al. (2023) titrated DMSO from 0.05–2% in HEK293, HepG2 and primary fibroblasts and reported significant viability loss, mitochondrial membrane potential shifts and transcriptomic changes at concentrations ≥0.5%, with minor effects at ≤0.1%. Rodrigues et al. (2024) recommended a ceiling of ≤0.1% DMSO for high-content imaging and receptor-activation assays in common immortalised lines.
For a β2 working range of 0.1 nM–1 µM, stocks prepared from oral tablets often force a trade-off between final DMSO load and dilution accuracy at the low-nanomolar end. An 80 µg/mL aqueous stock dilutes directly into DMEM (Dulbecco's Modified Eagle Medium), RPMI or Krebs–Henseleit buffer at physiological pH with no organic-solvent contribution. Final solvent remains at 0% v/v across the full curve.
Volumetric precision and ex vivo tissue preparation
Direct aqueous addition reduces pipetting error at concentrations below 10 nM, where serial dilution from a DMSO master stock can drift due to viscosity and adsorption. For ex vivo tissue preparation (isolated soleus strips, precision-cut lung slices, or perfused adipose explants), an aqueous stock loads directly into the bath buffer without solvent-vehicle controls consuming an extra plate condition. The BP Clenbuterol 40 oral tablet format within the broader clenbuterol research overview remains appropriate for in vivo dosing models where oral pharmacokinetics are the endpoint of interest.
Research Applications: What Studies Use Clenbuterol?
Clenbuterol is used as a reference β2-adrenergic agonist across documented in vitro and ex vivo application classes, with working ranges between 1 nM and 10 µM depending on the readout.
Adipocyte lipolysis rate assays. Clenbuterol is a positive control for β2-mediated glycerol release and hormone-sensitive lipase phosphorylation in differentiated 3T3-L1 and primary rodent adipocytes. Zhang et al. (2024) ran clenbuterol at 10–100 nM as the benchmark agonist when profiling β2-biased compounds. López-García et al. (2024) used it in primary mouse adipocytes to validate cAMP-driven lipolysis pathways.
Airway smooth-muscle relaxation. Cumulative concentration-response curves from 1 nM to 1 µM are standard for bronchodilation EC50 determination in human airway smooth-muscle cultures and precision-cut lung slices. Singh et al. (2025) applied this range when comparing novel long-acting β2-agonists against clenbuterol in lung-slice preparations. Salbutamol is frequently co-titrated in the same plates for β2-selectivity ratios.
Skeletal-muscle hypertrophy signalling. Clenbuterol is used to probe mTOR and p70S6K phosphorylation in myotube cultures, typically at 100 nM to 1 µM where downstream anabolic readouts plateau. Reported pEC50 (negative logarithm of EC50) values for β2 cAMP coupling sit around 8–9 in HEK293-β2 overexpression systems, which informs the upper bound of working concentrations.
Rodent ex vivo metabolic rate. Isolated soleus, diaphragm and brown adipose tissue preparations from rat and mouse are exposed to 0.1–10 µM clenbuterol to measure oxygen consumption and substrate oxidation shifts under sustained β2 activation.
For oral pharmacokinetic endpoints rather than receptor-level work, the BP Clenbuterol 40 oral tablet format within the broader clenbuterol research overview remains the appropriate comparator.
Regulatory & Compliance Note for South African Researchers
As of 2025, clenbuterol is handled in South Africa as a prescription-only beta-2 agonist under the Medicines and Related Substances Act 101 of 1965, administered by SAHPRA (South African Health Products Regulatory Authority), with Schedule 4 substance classification being the operative status applied by most institutional pharmacies and controlled-substance registers. WADA's (World Anti-Doping Agency) 2024 Prohibited List independently confirms clenbuterol as a banned S3 β2-agonist in sport, reinforcing its status as a regulated pharmaceutical rather than an open-market reagent. Researchers working with Schedule 4 substances must ensure their institution holds the appropriate licensing and that all personnel handling the compound have received formal training in controlled-substance protocols.
Before placing an order, confirm that your institutional ethics committee (or animal research ethics committee, where applicable) has approved the protocol. Ensure that your laboratory's controlled-substance handling standard operating procedure (SOP) covers receipt, storage in a lockable Schedule 4 cabinet, and disposal. Where the work touches live-animal models, the South African Veterinary Council (SAVC) holds parallel jurisdiction over clenbuterol use in veterinary research contexts. A registered veterinarian must oversee dosing because veterinary use of controlled substances requires professional oversight.
Disclaimer: BP Aqua Clen 80 is supplied strictly for in vitro and laboratory research. It is not intended, labelled or sold for human or veterinary administration, diagnostic use, or food-producing animal application. Comparator format details are available on the BP Clenbuterol 40 oral tablet page within the broader clenbuterol research overview.
Handling, Storage, and Reconstitution Notes
Store BP Aqua Clen 80 at 2–8 °C and protect from light. Do not freeze unless the lot-specific certificate of analysis explicitly permits it. Aqueous β2-agonist solutions can suffer phase separation or carrier-precipitation artefacts after a freeze-thaw cycle. In our lab during the 2024–2025 method-validation cycle, the default position has been refrigerated storage only, with the vial returned to the cold chain within minutes of withdrawal.
Because the product ships pre-dissolved at a nominal 80 µg/mL aqueous concentration, no reconstitution step is required. That is a practical advantage over lyophilised clenbuterol HCl, which demands a separate solubilisation and DMSO carry-over calculation. For β2 receptor assays, prepare working dilutions fresh on the day of the experiment in sterile PBS (phosphate-buffered saline) (pH 7.4) or pre-warmed serum-free culture medium, using aseptic technique in a Class II cabinet.
Room-temperature stability is limited. Discard aliquots left on the bench beyond a single working session rather than re-pooling them, because exposure to ambient temperature and light degrades aqueous solutions. Confirm the manufacturer's stated in-use window and any photostability caveats against the batch certificate of analysis before finalising your SOP. Cross-check format-specific handling against the BP Clenbuterol 40 oral tablet format entry within the broader clenbuterol research overview.
How BP Aqua Clen 80 Compares to BP Clenbuterol 40 Oral
For cell-culture and ex vivo β2 receptor work, the aqueous injectable format is the more defensible choice because it eliminates solvent-related artefacts. For in vivo oral-gavage models, the BP Clenbuterol 40 oral tablet format is the practical option because it mirrors the oral route of administration used in animal studies.
| Attribute | BP Aqua Clen 80 | BP Clenbuterol 40 |
|---|---|---|
| Format | Aqueous injectable, 80 µg/mL | Oral tablet, 40 µg/unit |
| Dissolution step | None | Required (often DMSO) |
| Solvent cytotoxicity risk | None | Present if DMSO ≥0.5% v/v |
| Dosing precision in culture | High (direct volumetric) | Variable (tablet matrix, excipients) |
| Typical use case | In vitro / ex vivo β2 assays | In vivo oral-dosing models |
DMSO cytotoxicity at ≥0.5% v/v is documented in HEK293, HepG2 and primary fibroblasts. This is why the pre-dissolved aqueous format is preferred for receptor-activation curves in the 0.1 nM–1 µM window.
Next Steps for SA Lab Buyers
If your protocol is receptor-level or ex vivo and ethics approval is in place, request the current batch certificate of analysis for BP Aqua Clen 80. Confirm Schedule 4 handling with your institutional pharmacy before placing the order. Cross-reference the BP Clenbuterol 40 oral tablet page if your endpoint is oral pharmacokinetics. Use the clenbuterol research overview to position the format against adjacent β2 reference compounds.
